Chemicals · Founded 1965 · www.transpek.com · BSE 506687 · NSE TRANSPEK · ISIN INE687A01016
No Notes Added Yet
Business
Transpek Industry Ltd. is an Indian specialty chemical manufacturer. The company primarily produces a range of performance and specialty chemicals, including Sulphur-based chemicals (e.g., Thionyl Chloride, Sulphuric Acid derivatives, Chlorosulphonic Acid), Anhydrous Aluminum Chloride, and various other chemical intermediates. These products serve a diverse set of end-use industries such as pharmaceuticals, agrochemicals, polymers, dyes, textiles, personal care, and automotive. Transpek operates on a business-to-business (B2B) model, selling its manufactured chemicals to other industrial customers. The company focuses on developing customized and complex chemical solutions, leveraging its R&D capabilities and manufacturing expertise.
Revenue Mix
Transpek Industry Ltd. does not typically report its revenue segmented by distinct product lines (e.g., Sulphur chemicals vs. Aluminium Chloride) or end-user industries in its standard disclosures. However, its product portfolio broadly covers:
Sulphur-based chemicals: A significant part of their offerings, used across many industries.
Chlorination products: Including Anhydrous Aluminum Chloride, vital for organic synthesis.
Other intermediates: Specialized chemicals for various applications.
The company's revenue is generated from the sale of these chemical products to its industrial customer base.
Industry
Transpek operates within the fragmented yet growing Indian chemicals sector, specifically in specialty and performance chemicals. The industry is characterized by increasing demand from diverse end-use sectors and a global shift towards India as a manufacturing hub ("China+1" strategy). Transpek is a mid-sized player, known for its expertise in certain niche chemistries like sulphur chlorination and anhydrous aluminium chloride. Its positioning is built on strong R&D, long-standing customer relationships, and quality products, competing with both larger diversified chemical companies and smaller niche players in specific product categories.
MOAT
Process Expertise & R&D: Transpek has developed proprietary manufacturing processes for complex chemicals, offering efficiency and quality advantages. Its dedicated R&D focuses on new product development and process optimization.
Customer Approvals & Relationships: In specialty chemicals, getting product approvals and building trust with B2B customers is a lengthy process, creating high switching costs once a supplier is established. Transpek benefits from long-term relationships with key clients.
Backward Integration: For some of its key products, the company has backward integration, which helps in managing raw material quality, ensuring supply security, and potentially optimizing costs.
Niche Focus: Expertise in specific, often hazardous or complex, chemistries (e.g., handling Sulphur and Chlorine) creates barriers to entry for new players.
Growth Drivers
Growth in End-User Industries: Sustained demand from its key client sectors like pharmaceuticals, agrochemicals, polymers, and personal care will drive demand for its specialty chemical products.
New Product Development & Commercialization: The company's R&D focus on developing new derivatives and chemistries for emerging applications can expand its market reach and product portfolio.
Import Substitution & "Make in India": Government initiatives and a global trend towards reducing reliance on single-country supply chains could boost domestic manufacturing and demand for Transpek's products.
Capacity Expansion: Any future capacity additions for high-demand products would directly contribute to volume growth.
Risks
Raw Material Price Volatility: The company is susceptible to fluctuations in the prices of key raw materials like Sulphur, Aluminum, and various basic chemicals, which can impact profit margins.
Environmental & Regulatory Risks: The chemical industry is subject to stringent environmental norms. Any changes in regulations or non-compliance could lead to operational disruptions or penalties.
Intense Competition: The specialty chemicals market is competitive, with both domestic and international players vying for market share.
Economic Slowdown: A downturn in the global or Indian economy could reduce demand from end-user industries, impacting sales volumes and realizations.
Forex Fluctuations: Significant import of raw materials or export of finished goods exposes the company to foreign exchange rate volatility.
Management & Ownership
Transpek Industry Ltd. is promoted by the Ghia family, who have a long history in the Indian chemical industry. The management team has significant experience in the specialty chemicals sector, guiding the company's strategic direction, R&D efforts, and operational efficiency. The promoter group typically holds a substantial stake in the company, reflecting a long-term commitment. Ownership also includes institutional investors and public shareholders.
Outlook
Transpek Industry Ltd. is well-positioned to benefit from the secular growth trends in the Indian specialty chemicals sector, driven by increasing domestic consumption and global supply chain diversification. Its strong R&D capabilities and focus on niche, complex chemistries provide a competitive edge and potential for new product development. However, the company faces inherent challenges common to the chemical industry, including raw material price volatility, environmental compliance costs, and competition. Sustained growth will depend on its ability to effectively manage input costs, successfully commercialize new products, and navigate evolving regulatory landscapes while capitalizing on its established customer relationships and process expertise.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 148 | 152 | 163 | 170 | 165 | 154 | 160 | 158 | 148 | 151 |
| Other Income | 5 | 11 | 5 | 5 | 8 | 12 | 5 | 4 | 4 | 4 |
| Total Income | 153 | 163 | 168 | 175 | 173 | 166 | 165 | 162 | 152 | 155 |
| Total Expenditure | 129 | 136 | 140 | 146 | 133 | 130 | 134 | 134 | 130 | 131 |
| Operating Profit | 24 | 27 | 28 | 29 | 40 | 36 | 32 | 28 | 22 | 24 |
| Interest | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 11 | 12 | 13 | 12 | 13 | 12 | 12 | 12 | 12 | 11 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 9 | 12 | 12 | 14 | 25 | 21 | 17 | 14 | 9 | 12 |
| Provision for Tax | 3 | 2 | 2 | 3 | 5 | 5 | 4 | 4 | 2 | 3 |
| Profit After Tax | 6 | 9 | 10 | 11 | 19 | 16 | 13 | 11 | 7 | 9 |
| Adjustments | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 6 | 9 | 10 | 11 | 19 | 16 | 13 | 11 | 7 | 9 |
| Adjusted Earnings Per Share | 10.1 | 16.6 | 17.1 | 19.1 | 34.5 | 27.9 | 22.6 | 19.4 | 11.8 | 16 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 284 | 317 | 361 | 595 | 566 | 339 | 599 | 827 | 580 | 650 | 621 | 617 |
| Other Income | 4 | 7 | 10 | 18 | 17 | 17 | 29 | 18 | 25 | 29 | 25 | 17 |
| Total Income | 288 | 324 | 371 | 612 | 583 | 357 | 628 | 845 | 605 | 679 | 646 | 634 |
| Total Expenditure | 237 | 264 | 314 | 478 | 448 | 292 | 503 | 680 | 497 | 555 | 528 | 529 |
| Operating Profit | 51 | 60 | 57 | 134 | 135 | 64 | 125 | 165 | 107 | 123 | 118 | 106 |
| Interest | 11 | 9 | 12 | 19 | 16 | 10 | 11 | 19 | 14 | 12 | 8 | 8 |
| Depreciation | 8 | 9 | 10 | 14 | 26 | 29 | 30 | 33 | 38 | 50 | 49 | 47 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 32 | 42 | 35 | 101 | 94 | 26 | 84 | 113 | 56 | 62 | 61 | 52 |
| Provision for Tax | 10 | 12 | 9 | 36 | 21 | 2 | 19 | 29 | 17 | 13 | 16 | 13 |
| Profit After Tax | 21 | 30 | 26 | 66 | 73 | 23 | 65 | 83 | 39 | 49 | 46 | 40 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 21 | 30 | 26 | 66 | 73 | 23 | 65 | 83 | 39 | 49 | 46 | 40 |
| Adjusted Earnings Per Share | 36.2 | 53.7 | 47.3 | 117.7 | 130.6 | 41.7 | 117.1 | 149.5 | 69 | 87.3 | 81.7 | 69.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -4% | -9% | 13% | 8% |
| Operating Profit CAGR | -4% | -11% | 13% | 9% |
| PAT CAGR | -6% | -18% | 15% | 8% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 3% | -9% | -9% | 11% |
| ROE Average | 6% | 6% | 10% | 15% |
| ROCE Average | 9% | 10% | 13% | 17% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 91 | 206 | 247 | 311 | 338 | 380 | 484 | 587 | 673 | 745 | 767 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 26 | 25 | 85 | 69 | 45 | 44 | 35 | 28 | 20 | 21 | 14 |
| Other Non-Current Liabilities | 18 | 46 | 51 | 64 | 70 | 69 | 79 | 137 | 160 | 113 | 94 |
| Total Current Liabilities | 74 | 109 | 183 | 154 | 136 | 106 | 166 | 136 | 113 | 122 | 133 |
| Total Liabilities | 209 | 386 | 566 | 599 | 589 | 599 | 764 | 887 | 966 | 1001 | 1008 |
| Fixed Assets | 94 | 117 | 179 | 236 | 287 | 287 | 295 | 365 | 397 | 360 | 343 |
| Other Non-Current Assets | 20 | 150 | 211 | 189 | 143 | 158 | 225 | 287 | 355 | 340 | 329 |
| Total Current Assets | 95 | 119 | 177 | 173 | 159 | 154 | 244 | 234 | 214 | 301 | 337 |
| Total Assets | 209 | 386 | 566 | 599 | 589 | 599 | 764 | 887 | 966 | 1001 | 1008 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 2 | 0 | 1 | 0 | 0 | 15 | 2 | 5 | 8 | 57 |
| Cash Flow from Operating Activities | 44 | 47 | 7 | 128 | 111 | 35 | 47 | 111 | 98 | 135 | 78 |
| Cash Flow from Investing Activities | -16 | -31 | -103 | -45 | -33 | -17 | -70 | -13 | -32 | -30 | -38 |
| Cash Flow from Financing Activities | -27 | -17 | 96 | -83 | -77 | -3 | 9 | -94 | -64 | -56 | -40 |
| Net Cash Inflow / Outflow | 1 | -1 | 0 | -0 | 0 | 15 | -14 | 4 | 3 | 48 | 1 |
| Closing Cash & Cash Equivalent | 2 | 0 | 1 | 0 | 0 | 15 | 2 | 5 | 8 | 57 | 58 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 36.24 | 53.67 | 47.27 | 117.69 | 130.59 | 41.74 | 117.09 | 149.45 | 69.03 | 87.25 | 81.72 |
| CEPS(Rs) | 50.38 | 69.12 | 65.04 | 143.01 | 176.96 | 92.77 | 170.31 | 208.57 | 136.35 | 176.75 | 168.8 |
| DPS(Rs) | 7.5 | 9 | 9 | 20 | 12.5 | 7.5 | 22.5 | 27.5 | 14 | 20 | 20 |
| Book NAV/Share(Rs) | 154.54 | 368.13 | 442.09 | 557.51 | 605.92 | 679.98 | 867.04 | 1050.26 | 1205.58 | 1334.36 | 1373.96 |
| Core EBITDA Margin(%) | 15.87 | 16.08 | 12.95 | 19.61 | 20.83 | 13.9 | 15.99 | 17.77 | 14.17 | 14.57 | 15.03 |
| EBIT Margin(%) | 14.36 | 15.72 | 12.9 | 20.23 | 19.32 | 10.59 | 15.81 | 15.94 | 12.03 | 11.29 | 11.15 |
| Pre Tax Margin(%) | 10.75 | 12.94 | 9.63 | 17.04 | 16.52 | 7.52 | 14.05 | 13.62 | 9.56 | 9.49 | 9.85 |
| PAT Margin (%) | 7.22 | 9.15 | 7.26 | 11.06 | 12.89 | 6.87 | 10.91 | 10.08 | 6.64 | 7.5 | 7.35 |
| Cash Profit Margin (%) | 10.04 | 11.78 | 9.99 | 13.43 | 17.46 | 15.26 | 15.87 | 14.06 | 13.11 | 15.19 | 15.18 |
| ROA(%) | 9.72 | 10.06 | 5.54 | 11.28 | 12.29 | 3.92 | 9.59 | 10.11 | 4.16 | 4.96 | 4.54 |
| ROE(%) | 25.71 | 20.23 | 11.67 | 23.55 | 22.45 | 6.49 | 15.14 | 15.59 | 6.12 | 6.87 | 6.03 |
| ROCE(%) | 27.58 | 22.98 | 12.62 | 26.57 | 24.27 | 7.81 | 17.43 | 20.66 | 10.11 | 9.79 | 8.7 |
| Receivable days | 79.21 | 63.12 | 80.65 | 57.37 | 59.07 | 89.16 | 53.36 | 47.88 | 65.98 | 54.6 | 74.28 |
| Inventory Days | 40.35 | 41.68 | 41.69 | 31.33 | 34.1 | 46.44 | 31.31 | 28.94 | 40.71 | 36.93 | 34.51 |
| Payable days | 97.06 | 66.62 | 83.88 | 68.95 | 78.11 | 99.15 | 53.67 | 46.13 | 63.56 | 60.09 | 83.57 |
| PER(x) | 10.93 | 11 | 26.09 | 12.77 | 9.41 | 32.67 | 16.66 | 9.84 | 25.78 | 14.29 | 10.72 |
| Price/Book(x) | 2.56 | 1.6 | 2.79 | 2.7 | 2.03 | 2.01 | 2.25 | 1.4 | 1.48 | 0.93 | 0.64 |
| Dividend Yield(%) | 1.89 | 1.52 | 0.73 | 1.33 | 1.02 | 0.55 | 1.15 | 1.87 | 0.79 | 1.6 | 2.28 |
| EV/Net Sales(x) | 1.03 | 1.32 | 2.46 | 1.65 | 1.4 | 2.46 | 1.95 | 1.06 | 1.74 | 0.97 | 0.67 |
| EV/Core EBITDA(x) | 5.79 | 6.92 | 15.66 | 7.31 | 5.86 | 12.94 | 9.38 | 5.3 | 9.38 | 5.12 | 3.54 |
| Net Sales Growth(%) | -2.04 | 11.59 | 14.08 | 64.64 | -4.87 | -40 | 76.52 | 38.02 | -29.9 | 12.12 | -4.41 |
| EBIT Growth(%) | 6.61 | 21.73 | -8.91 | 156.33 | -9.06 | -67.13 | 163.67 | 39.3 | -47.08 | 5.05 | -5.65 |
| PAT Growth(%) | -3.14 | 40.88 | -11.92 | 148.98 | 10.96 | -68.04 | 180.55 | 27.64 | -53.81 | 26.4 | -6.34 |
| EPS Growth(%) | -3.14 | 48.1 | -11.92 | 148.98 | 10.96 | -68.04 | 180.55 | 27.64 | -53.81 | 26.4 | -6.34 |
| Debt/Equity(x) | 0.7 | 0.43 | 0.82 | 0.46 | 0.32 | 0.25 | 0.27 | 0.13 | 0.07 | 0.05 | 0.06 |
| Current Ratio(x) | 1.28 | 1.09 | 0.97 | 1.12 | 1.17 | 1.44 | 1.47 | 1.73 | 1.9 | 2.47 | 2.54 |
| Quick Ratio(x) | 0.77 | 0.75 | 0.72 | 0.76 | 0.8 | 1.1 | 1.07 | 1.25 | 1.33 | 1.92 | 2.16 |
| Interest Cover(x) | 3.98 | 5.66 | 3.94 | 6.34 | 6.9 | 3.45 | 8.99 | 6.87 | 4.87 | 6.25 | 8.59 |
| Total Debt/Mcap(x) | 0.27 | 0.27 | 0.29 | 0.17 | 0.16 | 0.12 | 0.12 | 0.1 | 0.04 | 0.05 | 0.09 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 57.47 | 57.47 | 57.47 | 57.47 | 57.47 | 57.47 | 57.47 | 57.47 | 57.47 | 57.27 |
| FII | 0.05 | 0.05 | 0.05 | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 |
| DII | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 | 1.76 | 1.57 | 1.57 | 1.53 | 0.98 |
| Public | 40.69 | 40.69 | 40.69 | 40.71 | 40.71 | 40.73 | 40.93 | 40.93 | 40.98 | 41.73 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Public | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -4% | -9% | +13% | +8% |
| Operating Profit CAGR | -4% | -11% | +13% | +9% |
| PAT CAGR | -6% | -18% | +15% | +8% |
| Share Price CAGR | +3% | -9% | -9% | +11% |
| ROE Average | +6% | +6% | +10% | +15% |
| ROCE Average | +9% | +10% | +13% | +17% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 57.47 | 57.47 | 57.47 | 57.47 | 57.47 | 57.47 | 57.47 | 57.47 | 57.47 | 57.27 |
| FII | 0.05 | 0.05 | 0.05 | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 |
| DII | 1.79 | 1.79 | 1.79 | 1.79 | 1.79 | 1.76 | 1.57 | 1.57 | 1.53 | 0.98 |
| Public | 40.69 | 40.69 | 40.69 | 40.71 | 40.71 | 40.73 | 40.93 | 40.93 | 40.98 | 41.73 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Public | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.